AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00267-07v1
51/9/3465    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quinteira, S.
Right arrow Articles by Peixe, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quinteira, S.
Right arrow Articles by Peixe, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3465-3466, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00267-07

LETTER TO THE EDITOR

Molecular Epidemiology of Imipenem-Resistant Acinetobacter haemolyticus and Acinetobacter baumannii Isolates Carrying Plasmid-Mediated OXA-40 from a Portuguese Hospital{triangledown}


   LETTER
Top
 LETTER
REFERENCES
 
Major outbreaks of multidrug-resistant Acinetobacter baumannii associated with nosocomial infections have been increasingly reported worldwide (1, 10, 12). The endemicity of an OXA-24/40-producing A. baumannii clone associated with mortality events in Portugal has been observed at numerous hospitals within the Iberian Peninsula (5, 6, 10). Inversely, Acinetobacter haemolyticus, isolated only occasionally from clinical samples (9), usually presents susceptibility to different antibiotics, including ß-lactams (13). The isolation of two carbapenem-resistant A. haemolyticus strains prompted us to assess the relative contribution of clonal spread to the observed high rate of carbapenem-resistant Acinetobacter spp. in a general hospital in Porto, Portugal.

Between January 2001 and October 2004, 224 imipenem-resistant Acinetobacter spp. were collected from several specimen sources and different hospital wards, where A. baumannii was associated with nosocomial infections and colonizations for several months (Table 1). Imipenem resistance significantly increased from 2001 to 2002 and from 2002 to 2003. Macrorestriction analysis of genomic DNA by pulsed-field gel electrophoresis (5) and 16S rRNA gene sequencing, performed for each clone and species representative, showed that, with the exception of two clonally related A. haemolyticus isolates, the remainder were A. baumannii isolates, distributed among three different pulsotypes. Clonal dissemination of two major pulsotypes (A and B), widespread throughout the hospital, contributed to the observed A. baumannii imipenem resistance, which has persisted since at least 2001 despite several elimination attempts, including the use of polymyxin. Pulsotype B was predominant from 2001 to 2002, after which clone A emerged as the dominant type (Table 1). This clone was found to be identical to the previously described Iberian OXA-24/40-producing clone (5). Pulsotype C, with only two isolates, seemed to represent a sporadic event within the observed prevalence of clones A and B. Antimicrobial susceptibilities varied among isolates according to clones (Table 2). A. haemolyticus isolates presented resistance to all ß-lactams, with the exception of cefepime, ceftazidime, and aztreonam. All Acinetobacter sp. isolates were resistant to ciprofloxacin, whereas susceptibility to aminoglycosides was variable. Only 11 isolates (including the two A. haemolyticus isolates) showed a colistin MIC of ≥4 µg/ml (2). However, when the recently updated CLSI susceptible interpretative criterion of ≤2 µg/ml (3, 8) was applied, the susceptibility rate dropped from 96.1% to 92.1%. Detection of carbapenemase production, ulteriorly identified as an OXA-24/40 enzyme, was performed as previously described (5) and was positive only for clone A A. baumannii isolates and, for the first time, A. haemolyticus isolates. Hybridization assays after both S1 nuclease digestion and I-CeuI digestion, performed as previously described (7), revealed that although some clone A A. baumannii isolates showed a chromosome-positive signal (ca. 150 kb) for the blaOXA-24/40 probe, most also presented a positive hybridization in plasmidic bands of ca. 180 kb and ca. 30 kb. Similar hybridization signals were observed in the A. haemolyticus isolates. Further studies on plasmid characterization, assessing the homology among different plasmids, are ongoing.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Clinical data for imipenem-resistant Acinetobacter spp.a

 

View this table:
[in this window]
[in a new window]

  		TABLE 2. In vitro susceptibilities of imipenem-resistant Acinetobacter sp. clinical isolates

 
We describe, for the first time, the presence of an OXA-24/40 enzyme in an A. haemolyticus clinical isolate. Although the spread of OXA-24/40, both in the Iberian Peninsula and in France, has been correlated with the progressive dissemination of a single A. baumannii clone, the observation of this enzyme in a different, previously unreported, genomic species, A. haemolyticus, poses new questions on OXA-24/40 dissemination. It now seems reasonable to suspect a horizontal dissemination of the blaOXA-40 gene between different species, an ability supported by the observation of this enzyme, previously described as chromosomally encoded (7), in a plasmid. Notwithstanding, the dissemination of "successful" clones may possibly contribute to the high rates and persistence of imipenem-resistant A. baumannii isolates (4).


   ACKNOWLEDGMENTS
 
We are grateful to Nuno Monteiro for helpful discussions and critical review of the manuscript.


   FOOTNOTES
 
{triangledown} Published ahead of print on 2 July 2007. Back


   REFERENCES
Top
 LETTER
 REFERENCES
 

  1. Afzal-Shah, M., and D. M. Livermore. 1998. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J. Antimicrob. Chemother. 41:576-577.[Free Full Text]
  2. Catchpole, C., J. Andrews, N. Brenwald, and R. Wise. 1997. A reassessment of the in vitro activity of colistin sulphomethate. J. Antimicrob. Chemother. 39:255-260.[Abstract/Free Full Text]
  3. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement, vol. 26. M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
  4. Coelho, J., J. Turton, M. Kaufmann, J. Glover, N. Woodford, M. Warner, M. Palepou, R. Pike, T. Pitt, B. Patel, and D. Livermore. 2006. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J. Clin. Microbiol. 44:3623-3627.[Abstract/Free Full Text]
  5. Da Silva, G., S. Quinteira, E. Bértolo, J. Sousa, L. Gallego, A. Duarte, and L. Peixe. 2004. Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumannii clone in the Iberian Peninsula. J. Antimicrob. Chemother. 54:255-258.[Abstract/Free Full Text]
  6. Gallego, L., and K. Towner. 2001. Carriage of class 1 integrons and antibiotic resistance in clinical isolates of Acinetobacter baumannii from northern Spain. J. Med. Microbiol. 50:71-77.[Abstract/Free Full Text]
  7. Héritier, C., L. Poirel, D. Aubert, and P. Nordmann. 2003. Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob. Agents Chemother. 47:268-273.[Abstract/Free Full Text]
  8. Jones, R., T. Anderegg, and J. Swenson. 2005. Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J. Clin. Microbiol. 43:925-927.[Abstract/Free Full Text]
  9. Lambert, T., G. Gerbaud, M. Galimand, and P. Courvalin. 1993. Characterization of Acinetobacter haemolyticus aac(6')-Ig gene encoding an aminoglycoside 6'-N-acetyltransferase which modifies amikacin. Antimicrob. Agents Chemother. 37:2093-2100.[Abstract/Free Full Text]
  10. Lopez-Otsoa, F., L. Gallego, K. Towner, L. Tysall, N. Woodford, and D. Livermore. 2002. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J. Clin. Microbiol. 40:4741-4743.[Abstract/Free Full Text]
  11. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
  12. Poirel, L., and P. Nordmann. 2006. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 12:826-836.[CrossRef][Medline]
  13. Visalli, M., M. Jacobs, T. Moore, F. Renzi, and P. Appelbaum. 1997. Activities of ß-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods. Antimicrob. Agents Chemother. 41:767-770.[Abstract]
Sandra Quinteira
REQUIMTE
Instituto Politécnico da Saúde do Norte-ESSVA
VN Famalicão
Porto, Portugal

Filipa Grosso
REQUIMTE
Laboratório de Microbiologia
Faculdade de Farmácia
Universidade do Porto
Porto, Portugal

Helena Ramos
Hospital Geral de Santo António
Porto, Portugal

Luísa Peixe*
REQUIMTE
Laboratório de Microbiologia
Faculdade de Farmácia
Universidade do Porto
Rua Aníbal Cunha
164 4050-047 Porto, Portugal

* Phone: 351-222078946 Fax: 351-222003977 E-mail: lpeixe{at}ff.up.pt

Antimicrobial Agents and Chemotherapy, September 2007, p. 3465-3466, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00267-07





This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00267-07v1
51/9/3465    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quinteira, S.
Right arrow Articles by Peixe, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quinteira, S.
Right arrow Articles by Peixe, L.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS